ProRetina Therapeutics Overview

  • Founded
  • 2007
  • Status
  • Out of Business
  • Employees
  • 10
  • Latest Deal Type
  • Liquidation

ProRetina Therapeutics General Information


Developer of therapeutics and drugs designed to be used for the treatment of retinal dystrophies and degenerations. The company's products contain active ingredient, a neuroprotective agent which is highly effective in treating retinitis pigmentosa, a degenerative disease of genetic origins, enabling patients and healthcare institutions to avail cure to stop blindness in the adult age.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Plaza CEIN, 5
  • 31110 Noáin
  • Spain
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ProRetina Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Bankruptcy: Liquidation 30-Sep-2018 00.000 Completed Bankruptcy: Liquidation
5. Early Stage VC (Series A) 15-Aug-2013 00.000 Completed Generating Revenue
4. Grant 00.000 Completed Startup
3. Seed Round 15-Sep-2012 00.000 00.000 Completed Startup
2. Early Stage VC 24-Sep-2010 $490K $3.88M Completed Startup
1. Early Stage VC 02-Apr-2010 $3.39M $3.39M Completed Startup
To view ProRetina Therapeutics’s complete valuation and funding history, request access »

ProRetina Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial